- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06311500
Sleep Health Enhancement in Midlife Adults
December 18, 2025 updated by: University of Kansas Medical Center
Despite the strong links between sleep and AD, a sleep health enhancement has yet to be targeted in mid-life adults (45-64 years old) to delay or prevent AD.
An intervention aimed at enhancing sleep health is a critical opportunity for primary prevention to potentially delay the onset of AD.
The objective of the proposed study is to develop and assess the feasibility, acceptability, and treatment effect of a comprehensive sleep health intervention (SHI) on improving sleep health in mid-life adults
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 45-64 years old
- ≤ 7 on the RU-SATED self-report questionnaire
- MMSE ≥25 and AD8 <3
Exclusion Criteria:
- Known untreated sleep disorder (such as sleep apnea or restless leg syndrome)
- >3 on the STOP BANG indicating increased risk of sleep apnea
- Increased risk of restless legs syndrome on RLS-Diagnosis Index
- Evidence of circadian rhythm sleep-wake disorder
- Evidence of parasomnia
- Regular use (>2x/week) of prescription or over-the-counter medications to improve sleep
- Score of ≥15 on the Patient Health Questionnaire (PHQ-9) indicating severe depression or endorsement of any suicidal ideation (answer 1, 2 or 3 on #9 of the PHQ-9)
- Score of ≥10 on the Generalized Anxiety Disorder (GAD-7) indicating moderate to severe anxiety
- Self-report of current or history (up to 2 years) of drug or alcohol abuse based on the DSM-5-TR criteria
- History of nervous system disorder such as stroke or Parkinson's disease
- Severe mental illness such as schizophrenia or bipolar disorder
- Current or history (within 5 years) of shift work including hours of midnight-4am
- Is currently receiving a behavioral sleep health intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sleep Health Enhancement Intervention
4 weekly visits using Zoom video conferencing consisting of education and strategies to enhance sleep health with each visit lasting about 60 minutes.
|
4 weekly visits of education and strategies to enhance sleep health
|
|
No Intervention: Wait-List Control Group
People in the wait-list group will continue with their usual activities for 4 weeks and then start the sleep health enhancement intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6-item Acceptability Scale
Time Frame: immediately post-intervention
|
5-point Likert scales on ease of use, understandability, enjoyment, perceived helpfulness, time commitment, and overall satisfaction
|
immediately post-intervention
|
|
Qualitative interview
Time Frame: immediately post-intervention
|
semi-structured interview to assess acceptability
|
immediately post-intervention
|
|
Ru-SATED Composite score
Time Frame: baseline, Week 6, Week 12
|
Comprised of 6 subscores (regularity, timing, efficiency, and duration from actigraphy, satisfaction from sleep diary, and alertness from Epworth Sleepiness Scale)
|
baseline, Week 6, Week 12
|
|
Sleep Self-Efficacy Scale
Time Frame: baseline, Week 6, Week 12
|
9 item self-report Likert-scale questionnaire use to identify sleep self-efficacy.
|
baseline, Week 6, Week 12
|
|
Pittsburgh Sleep Quality Index
Time Frame: baseline, Week 6, Week 12
|
used to assess quality of sleep
|
baseline, Week 6, Week 12
|
|
Epworth Sleepiness Scale
Time Frame: baseline, Week 6, Week 12
|
used to assess daytime sleepiness
|
baseline, Week 6, Week 12
|
|
Dysfunctional Beliefs About Sleep (DBAS-10) consists of 10 statements reflecting beliefs and attitudes about sleep. Each statement is rated from 1 = strongly disagree to 10 = strongly agree
Time Frame: baseline, Week 6, Week 12
|
The DBAS-10 used to identify dysfunctional beliefs about sleep
|
baseline, Week 6, Week 12
|
|
Positive Affect and Negative Affect Schedule
Time Frame: baseline, Week 6, Week 12
|
20-item self-report questionnaire used to measure positive and negative emotions
|
baseline, Week 6, Week 12
|
|
Continuous Performance Test
Time Frame: baseline, Week 6, Week 12
|
requires participants to respond as quickly and accurately as possible to a series of stimuli that are delivered via computer.
The participants will be instructed to tap the space bar for every letter except "X."
|
baseline, Week 6, Week 12
|
|
Stroop Test
Time Frame: baseline, Week 6, Week 12
|
requires participants to inhibit the natural response (reading a word) and replace it with another response (saying a color)
|
baseline, Week 6, Week 12
|
|
Cognitive Failures Questionnaire
Time Frame: baseline, Week 6, Week 12
|
assesses perception of cognitive abilities over the past 6 months
|
baseline, Week 6, Week 12
|
|
Actigraphy
Time Frame: baseline, Week 6, Week 12
|
Participants will wear an actigraph on their non-dominant wrist for 7 nights to assess sleep/wake cycle.
Mains variables of interest are sleep regularity, timing, efficiency, and duration.
|
baseline, Week 6, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2024
Primary Completion (Actual)
November 19, 2025
Study Completion (Actual)
November 19, 2025
Study Registration Dates
First Submitted
January 12, 2024
First Submitted That Met QC Criteria
March 7, 2024
First Posted (Actual)
March 15, 2024
Study Record Updates
Last Update Posted (Actual)
December 26, 2025
Last Update Submitted That Met QC Criteria
December 18, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- STUDY00151143
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.